Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.
The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.
Jasper Therapeutics, Inc. reported a much smaller net loss for the six months ended June 30, 2026 of $3.9 million, compared with $48.0 million a year earlier. Operating expenses fell to $20.2 million from $48.9 million, reflecting prior restructuring, narrower R&D focus and lower general and administrative costs. Results also benefited from $13.6 million of non‑cash income from remeasuring warrant liabilities and a $2.3 million gain from reversing a CIRM grant liability.
Cash, cash equivalents and restricted cash declined to $7.7 million at June 30, 2026 from $29.1 million at year‑end 2025, after $21.5 million of operating cash outflows in the first half. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern over the next 12 months, even after considering cost‑control plans.
Subsequent to quarter‑end, Jasper closed the acquisition of Kira Pharmaceuticals and a related private placement of Non‑Voting Convertible Preferred Stock generating $132.0 million of gross proceeds, and entered into a $12.0 million upfront license agreement with Mirador Therapeutics. The company also put in place a $30.0 million contingent value right tied to a potential Priority Review Voucher for briquilimab.
Jasper Therapeutics, Inc., a Delaware biotechnology company, reports a private exempt equity offering under Rule 506(b) of Regulation D. The total amount of equity securities sold is $131,999,611, with $0 remaining to be sold, indicating the offering is fully subscribed. The first sale occurred on July 21, 2026. No finders’ fees are reported, with such expenses stated as $0. The company declines to disclose its revenue or asset size. The issuer is not registered as an investment company and operates in the health care biotechnology industry.
Jasper Therapeutics, Inc. reported that director Thomas G. Wiggans received an automatic grant of a stock option covering 7,500 shares of Voting Common Stock at an exercise price of $0.6300 per share. The option expires on 2036-07-31 and, under the Non-Employee Director Compensation Policy, vests in full on the first anniversary of the 2026-07-31 grant date, subject to his continued board service.
Jasper Therapeutics director Lucas Svetlana received an automatic grant of stock options covering 7,500 shares of Voting Common Stock. The options were awarded under the Non-Employee Director Compensation Policy at an exercise price of $0.6300 per share, vesting in full on the first anniversary of the grant, and leave Lucas holding 7,500 derivative securities.
Crutcher Patrick J reported acquisition or exercise transactions in this Form 4 filing.
Jasper Therapeutics, Inc. reported that director Patrick J. Crutcher received a stock option for 7,500 shares of Voting Common Stock on July 31, 2026, exercisable at $0.63 per share. The option vests in full one year after grant, subject to continued service, and expires July 31, 2036, leaving him holding 7,500 options directly.
Jasper Therapeutics, Inc. reported that director Kurt Von Emster received a grant of stock options covering 7,500 shares of Voting Common Stock at an exercise price of $0.6300 per share. The options were granted automatically under the Non-Employee Director Compensation Policy, vest on July 31, 2027, and expire on July 31, 2036.
Jasper Therapeutics, Inc. reported that director Judith Anne Shizuru received an automatic grant of a stock option for 7,500 shares of Voting Common Stock on July 31, 2026, under the Non-Employee Director Compensation Policy. The option has a $0.63 exercise price, vests in full on July 31, 2027, and expires on July 31, 2036, leaving her with 7,500 options held directly.
Jasper Therapeutics, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on July 31, 2026. A total of 21,121,396 shares of voting common stock, or approximately 75% of the 28,009,802 shares outstanding as of June 5, 2026, were represented virtually or by proxy.
For the election of two Class II directors, stockholders cast 9,273,875 votes for and 419,763 withheld for Judith Shizuru, M.D., Ph.D., and 9,280,610 votes for and 413,028 withheld for Tom Wiggans, with 11,427,758 broker non-votes for each nominee. On the proposal to ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, votes totaled 20,635,404 for, 434,262 against, and 51,730 abstentions. On the advisory vote regarding compensation of named executive officers, stockholders cast 9,016,797 votes for, 604,173 against, 72,668 abstentions, and 11,427,758 broker non-votes.
Jasper Therapeutics, Inc. describes contingent value rights granted in connection with its acquisition of Kira Pharmaceuticals. Each holder of voting common stock of Jasper of record immediately before the merger’s Effective Time is entitled to one contractual contingent value right (CVR) per share.
Each CVR gives the holder a pro rata portion of a $30.0 million Milestone Payment if the U.S. Food and Drug Administration issues a Priority Review Voucher for briquilimab on or before December 31, 2028. Payment timing depends on any Change of Control and a Monetization Event, with payment generally due within 90 days after monetization. The CVRs are generally non-transferable, not certificated, and not registered or listed. The record date for CVR eligibility was July 16, 2026, the closing date of the Kira acquisition.
Jasper Therapeutics, Inc. reports initial equity holdings for Chief Medical Officer Greg Keenan following the merger with Kira Pharmaceuticals. Keenan holds stock options at $0.0100 per share for 103,204 shares of Voting Common Stock and options at $0.6100 per share linked to 92,278 shares of Non-Voting Convertible Preferred Stock, received in exchange for 622,456 Kira options. These options begin vesting in equal monthly installments over 48 months starting June 10, 2026. Each share of Preferred Stock will automatically convert into 61 shares of Voting Common Stock after required stockholder approval, subject to a holder-set beneficial ownership cap between 4.9% and 19.9%, and the Preferred Stock has no expiration date.